Alamar Biosciences
Alamar Biosciences is a life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. The company leverages its proprietary NULISA (NUcleic Acid Linked Immuno-Sandwich Assay) technology and the ARGO HT System to detect biomarkers with ultra-high sensitivity, offering more than 10,000-fold improvement in signal-to-noise ratio compared to traditional immunoassay approaches.
Public Company
Alamar Biosciences is publicly traded
IPO'd on Apr 17, 2026
This company is no longer available on our private secondary market. Shares can be traded publicly under ALMR.
Overview
Company data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Founded
2018
Employees
201–500
Total Funding
$250M
6 rounds
Last Private Valuation
$1.08B
Feb 26, 2024
Secondary Signals (Note: SetterVC does not verify the accuracy of these)
1 signalClosed $56.5M oversubscribed convertible notes financing led by new investors T. Rowe Price and Braidwell LP
Bridge financing just ahead of the April 2026 IPO; notes converted to equity at listing
Funding
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Total raised $250M across 6 rounds
Last updated 09-03-2026
| Date | Round | Amount Raised | Valuation | Lead Investors |
|---|---|---|---|---|
| Apr 17, 2026 | IPO | $191.3M | $1.08B | |
| Jan 8, 2026 | Convertible Notes | $56.5M | — | Not disclosed |
| Sep 2025 | Venture Debt | $10M | — | Silicon Valley Bank |
Valuation Trajectory
Funding data and valuation marks are estimates and may be incomplete, stale, erroneous, or revised.
Entry · Series C
$1.1B
Feb 2024
Alamar Biosciences today
$1.1B
Apr 2026 · latest mark
Alamar Biosciences multiple
1.0x
valuation uplift since first round
Y-axis is logarithmic. Hollow dots = estimated valuations. Does not represent realized investor returns.
Prominent Investors
Leadership
Yuling Luo
Co-Founder, Chief Executive Officer & Chairman
Timothy "Tod" White
President
Justin McAnear
Chief Financial Officer
Shiping "Steve" Chen
Co-Founder & Chief Operating Officer
Stephen Williams
Chief Scientific Officer
Competitors
Competitor list is illustrative and may be incomplete, stale, or erroneous.
SomaLogic
Proteomics company specializing in protein biomarker detection using aptamer technology
Olink Proteomics
Swedish proteomics company providing protein biomarker analysis platforms
Quanterix
Biotech company offering ultra-sensitive protein detection and measurement solutions
Alamar Biosciences Investment FAQ
Alamar Biosciences FAQ
Yes, Alamar Biosciences is publicly traded under the ticker symbol ALMR on the NASDAQ. The company went public in Apr 17, 2026.
Alamar Biosciences trades under the ticker symbol ALMR on the NASDAQ. It began trading in Apr 17, 2026.
Alamar Biosciences (ALMR on the NASDAQ) shares can be purchased through any standard brokerage account — including Fidelity, Charles Schwab, TD Ameritrade, and online platforms like Robinhood or E*TRADE. Search for the ticker ALMR to place an order.
Alamar Biosciences went public in Apr 17, 2026 via ipo, with an offering valuation of approximately $1.08B. Alamar Biosciences priced an upsized initial public offering at $17.00 per share on April 16, 2026 and began trading on the Nasdaq Global Select Market under the ticker ALMR on April 17, opening at $22.60. The offering closed on April 20, 2026 covering 12,937,500 shares, including the underwriters' option exercised in full, for gross proceeds of $219.9 million and net proceeds of $197.8 million. All outstanding preferred stock and the January 2026 convertible notes converted into common stock at closing.
Alamar Biosciences raised $250M across 6 disclosed funding rounds prior to its public listing.
Alamar Biosciences was co-founded by Yuling Luo, and Shiping "Steve" Chen in 2018.
Alamar Biosciences is headquartered in Fremont, CA, United States.
Access live market data
Sign UpData collected with AI, which can make mistakes. Please double-check this information.